Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
Inhibikase Therapeutics, Inc. has a major shareholder group associated with RA Capital reporting indirect ownership of 25,000,000 shares of common stock as of July 10, 2026.
The shares are held directly by RA Capital Healthcare Fund LP, with RA Capital Management as investment manager and its principals Dr. Peter Kolchinsky and Mr. Rajeev Shah as managing members, each disclaiming beneficial ownership beyond their pecuniary interest.
Inhibikase Therapeutics, Inc. is reported to have 25,000,000 shares of its common stock held by RA Capital Healthcare Fund, L.P., with RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah as associated reporting persons. This position represents 15.9% of Inhibikase’s common stock.
The percentage is based on 132,032,636 shares outstanding as of May 1, 2026, plus 25,000,000 additional shares issued to the Fund in an at-the-market offering on July 10, 2026. The Fund has delegated sole voting and dispositive power over these shares to RA Capital and disclaims beneficial ownership, while the other reporting persons also disclaim beneficial ownership except for Section 13(d) reporting purposes.
Inhibikase Therapeutics, Inc. disclosed that it sold 25,000,000 shares of common stock to RA Capital Management through its at-the-market facility, generating gross proceeds of $50 million under an existing shelf registration statement on Form S-3 and related ATM prospectus supplement.
The company expects this additional capital, together with existing cash reserves, to support operations through topline data readout in Part B of its ongoing global Phase 3 IMPROVE-PAH trial of IKT-001 for Pulmonary Arterial Hypertension, subject to the full exercise of outstanding Series A and B Warrants.
Inhibikase is a clinical-stage pharmaceutical company developing IKT-001, a prodrug of imatinib, for Pulmonary Arterial Hypertension, a progressive, life-threatening disease that affects approximately 50,000 Americans, with its single pivotal Phase 3 IMPROVE-PAH study actively enrolling at about 180 sites worldwide.
Inhibikase Therapeutics director Dennis N. Berman received a stock option grant covering 155,000 shares of common stock. The option has an exercise price of $1.91 per share and expires on June 26, 2036.
The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to his continued service as a director through that date. After this grant, Berman holds stock options for 155,000 underlying shares directly.
Inhibikase Therapeutics, Inc. director David Canner received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.91 per share and expire on June 26, 2036.
The options vest on the earlier of June 26, 2027 or the day before the next annual stockholder meeting, contingent on his continued board service. Following this award, Canner holds 155,000 derivative securities directly.
Inhibikase Therapeutics, Inc. director Arvind Kush received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.91 per share and were awarded at no cost to the director.
The options vest on the earlier of June 26, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to his continued service as a director. Following this grant, he holds stock options for 155,000 underlying shares directly.
Inhibikase Therapeutics director Roberto Bellini received a grant of stock options for 155,000 shares of Common Stock. The options have an exercise price of $1.91 per share and expire on June 26, 2036. Following this grant, he holds 155,000 options directly.
The options will vest on the earlier of June 26, 2027 or the day before the next annual meeting of stockholders, as long as he continues to serve as a director through that date. This is a compensation-related award, not an open-market share purchase or sale.
Inhibikase Therapeutics, Inc. director Vincent Aurentz received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.9100 per share and expire on June 26, 2036. They vest on the earlier of June 26, 2027 or the day before the next annual stockholder meeting, subject to his continued board service.
Inhibikase Therapeutics, Inc. director Amit Munshi reported a compensation-related grant of stock options. He received options to acquire 155,000 shares of common stock at an exercise price of $1.91 per share, with no cash paid for the grant itself.
The options vest on the earlier of June 26, 2027 or the day before the next annual meeting of stockholders, conditioned on his continued service as a director through that date. After this grant, his reported stock option holdings from this award total 155,000 options, which are scheduled to expire on June 26, 2036.
Inhibikase Therapeutics, Inc. held its 2026 annual meeting of stockholders in a virtual format, where all six management proposals were approved. Stockholders backed an amendment to the 2020 Equity Incentive Plan, increasing the shares reserved for issuance by 3,000,000 common shares.
They also approved a Certificate of Amendment to limit the liability of certain officers as permitted by Delaware law, ratified CohnReznick LLP as independent auditor for 2026, and supported executive compensation on an advisory basis. Directors Arvind Kush and Dennis Berman were re‑elected as Class III directors, and investors chose to hold future say‑on‑pay votes annually.